Journal
CANCER SCIENCE
Volume 104, Issue 11, Pages 1396-1400Publisher
WILEY
DOI: 10.1111/cas.12275
Keywords
-
Categories
Funding
- Program for Promotion of Fundamental Studies in Health Sciences from the National Institute of Biomedical Innovation
- Ministry of Health, Labor, and Welfare
- National Cancer Center Research and Development Fund
- National Cancer Center Research and Development Fund, Japan
Ask authors/readers for more resources
Development of lung adenocarcinoma (LADC), the most frequent histological type of lung cancer, depends in many cases on the activation of driver oncogenes such as KRAS, epidermal growth factor receptor (EGFR), and anaplastic lymphoma kinase (ALK). Inhibitors that target the EGFR and ALK tyrosine kinases show therapeutic effects against LADCs containing EGFR gene mutations and ALK gene fusions, respectively. Recently, we and others identified the RET fusion gene as a new targetable driver gene in LADC. The RET fusions occur in 1-2% of LADCs. Existing US Food and Drug Administration-approved inhibitors of RET tyrosine kinase show promising therapeutic effects both in vitro and in vivo, as well as in a few patients. Clinical trials are underway to investigate the therapeutic effects of RET tyrosine kinase inhibitors, such as vandetanib (ZD6474) and cabozantinib (XL184), in patients with RET fusion-positive non-small-cell lung cancer.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available